These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25048494)

  • 21. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO; Mueller S; Akyol C; Erbel C; Frankenstein L; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: A randomized prospective study.
    Kim JM; Kwon CH; Joh JW; Sinn DH; Lee S; Choi GS; Lee SK
    Liver Transpl; 2016 Feb; 22(2):209-16. PubMed ID: 26360125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion From Cyclosporine to Once-Daily Tacrolimus on 50:1 mg Basis: A Short-Term Pilot Study.
    Shimada H; Uchida J; Kosoku A; Iwai T; Kabei K; Nishide S; Naganuma T; Kumada N; Takemoto Y; Nakatani T
    Exp Clin Transplant; 2020 Feb; 18(1):1-7. PubMed ID: 31180299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies.
    Vadcharavivad S; Saengram W; Phupradit A; Poolsup N; Chancharoenthana W
    Drugs; 2019 Dec; 79(18):1947-1962. PubMed ID: 31713065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study.
    Krämer BK; Charpentier B; Bäckman L; Silva HT; Mondragon-Ramirez G; Cassuto-Viguier E; Mourad G; Sola R; Rigotti P; Mirete JO;
    Am J Transplant; 2010 Dec; 10(12):2632-43. PubMed ID: 20840480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
    Fischer L; Saliba F; Kaiser GM; De Carlis L; Metselaar HJ; De Simone P; Duvoux C; Nevens F; Fung JJ; Dong G; Rauer B; Junge G;
    Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study.
    Sańko-Resmer J; Boillot O; Wolf P; Thorburn D
    Transpl Int; 2012 Mar; 25(3):283-93. PubMed ID: 22239105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation.
    Albano L; Banas B; Klempnauer JL; Glyda M; Viklicky O; Kamar N;
    Transplantation; 2013 Nov; 96(10):897-903. PubMed ID: 23982340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion From Twice-Daily to Once-Daily Tacrolimus Among Egyptian Living-Donor Kidney Allograft Recipients: A Single-Center Experience.
    Bakr MA; Nagib AM; Abbas MH; Donia AF
    Exp Clin Transplant; 2019 Oct; 17(5):594-598. PubMed ID: 31050617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation.
    Wu YJ; Lin YH; Yong CC; Li WF; Wang SH; Wang CC; Lin TL; Chen CL; Lin CC
    Ann Transplant; 2016 Jan; 21():30-4. PubMed ID: 26782179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial.
    Wlodarczyk Z; Squifflet JP; Ostrowski M; Rigotti P; Stefoni S; Citterio F; Vanrenterghem Y; Krämer BK; Abramowicz D; Oppenheimer F; Pietruck F; Russ G; Karpf C; Undre N
    Am J Transplant; 2009 Nov; 9(11):2505-13. PubMed ID: 19681813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge.
    Jannot M; Masson I; Alamartine E; Mariat C
    Ann Transplant; 2014 Jul; 19():320-4. PubMed ID: 24999809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Kidney Graft Recipients.
    Barreto P; Malheiro J; Vieira P; Pedroso S; Almeida M; Martins LS; Dias L; Henriques AC; Cabrita A
    Transplant Proc; 2016 Sep; 48(7):2276-2279. PubMed ID: 27742278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.
    Florman S; Alloway R; Kalayoglu M; Lake K; Bak T; Klein A; Klintmalm G; Busque S; Brandenhagen D; Lake J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):1211-3. PubMed ID: 15848672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten-Year Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant: A Prospective Cohort Study.
    Parodi EL; La Porta E; Russo R; Marsano L; Bellino D; Paoletti E; Massarino F; Sofia A; Garibotto G; Esposito P; Murugavel A; Cappadona F; Fontana I; Viazzi F; Picciotto D
    Transplant Proc; 2020 Dec; 52(10):3112-3117. PubMed ID: 32680595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal Function and Patient-Reported Outcomes in Stable Kidney Transplant Patients Following Conversion From Twice-Daily Immediate-Release Tacrolimus to Once-Daily Prolonged-Release Tacrolimus: A 12-Month Observational Study in Routine Clinical Practice in Germany (ADAGIO).
    Hugo C; Weihprecht H; Banas B; Schröppel B; Jank S; Arns W; Schenker P; Rath T; Hergesell O; Feldkamp T; Hermann B; Schiffer M
    Transplant Proc; 2021 Jun; 53(5):1484-1493. PubMed ID: 33610306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A; Poli L; Nofroni I; Bachetoni A; Tinti F; Umbro I; Barile M; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen.
    Han DJ; Park JB; Kim YS; Kim SJ; Ha J; Kim HC; Kim SJ; Moon IS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):115-7. PubMed ID: 22310592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment satisfaction in renal transplant patients taking tacrolimus once daily.
    van Boekel GA; Kerkhofs CH; Hilbrands LB
    Clin Ther; 2013 Nov; 35(11):1821-9.e1. PubMed ID: 24135441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.